Team announcement
NOXXON Pharma Appoints Dr. Oscar Izeboud to the Supervisory Board
NOXXON Pharma, a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment, announced that it has appointed Dr. C. A. (Oscar) Izeboud Izeboud") to its supervisory board. His two-year term began on June 30, 2020. Dr. Izeboud is the CEO of Scenic Biotech, a Dutch drug discovery and development company focused on genetic modifiers. He was previously a Managing Director at NIBC Bank N.V. and Kempen & Co. Before he joined the banking sector, Dr. Izeboud’s initial interest was in the biotech industry where he worked for a number of companies including Crucell NV, Specs BV, and TNO Pharma. Dr. Izeboud holds a Ph.D. in immunopharmacology from the University of Utrecht in the Netherlands. In a press release, NOXXON Pharma Chairman Dr. Maurizio PetitBon stated, “We are very pleased to welcome Oscar to the NOXXON supervisory board. He brings both a deep understanding of medicine and extensive experience in the financing and business side of biotechnology. While leading life science & healthcare banking at Kempen and NIBC, Oscar successfully closed more than 100 transactions, including 17 IPOs and 15 mergers or acquisitions. This experience combined with his operational biotech background will be incredibly valuable to refine and implement NOXXON’s strategy.”